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Purpose
Protease inhibitors may contribute to metabolic compli-
cations and cardiovascular risk associated with HIV
infection. Here we investigate metabolic changes follow-
ing treatment with darunavir/ritonavir (DRV/r)- com-
pared with atazanavir/ritonavir (ATV/r)-based therapy.
Methods
In this 48-week, Phase IV, multicenter, open-label, ran-
domized, exploratory study, HIV-1—infected, antiretro-
viral naïve adults were given DRV/r 800/100mg once
daily (qd) or ATV/r 300/100mg qd, both with tenofovir/
emtricitabine 300/200mg qd. Week 48 changes in fast-
ing lipids, glucose, insulin, insulin sensitivity, creatinine
clearance, biomarkers (inflammation, coagulation and
bacterial translocation), CD4 count, viral load (VL) and
safety are reported. Observed values and descriptive sta-
tistics are reported through Week 48 for intent-to-treat
and lipid evaluable populations.
Results
34 (median age, 37 years; men, n=29) and 31 (median age,
35 years; men, n=27) subjects were randomized to the
DRV/r arm and ATV/r arm, respectively. Of these, 29
DRV/r and 25 ATV/r subjects completed Week 48. At
Week 48, changes in fasting lipids and biomarkers were
similar between arms. Although rates of adverse events
(AEs) and laboratory abnormalities were comparable
between arms, ATV/r arm had higher rates of grade 2—4
hyperbilirubinemia (n=27 [87%] vs n=1 [3%]). At Week
48, 77% of DRV/r and 71% of ATV/r subjects had VL <50
copies/mL (confirmed virologic response). Table 1.
Conclusions
Changes from baseline to Week 48 in fasting lipids, glu-
cose, insulin, HOMA-IR, creatinine clearance, biomar-
kers, CD4 and VL were similar for DRV/r and ATV/r.
Given its favorable metabolic profile, which was main-
tained over 48 weeks, DRV/r provides a valuable thera-
peutic option for HIV-1—infected subjects.
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Changes in metabolic and efficacy
parameters from baseline to Week 48
DRV/r ATV/r Difference in mean change
between arms, (95% CI)
BL Change from BL
at Week 48
BL Change from BL
at Week 48
Fasting lipid parameters
a
TG, mg/dL
Mean (SD) 114 (57) 26 (69) 114 (84) 10 (74) 16.5 (—25.0, 58.0)
Median (IQR) 87 (77,
153)
11 (—15, 37) 90 (65,
119)
15 (—24, 54)
TC, mg/dL
Mean (SD) 142 (28) 22 (31) 165 (30) 12 (32) 10.5 (—7.7, 28.8)
Median (IQR) 136 (122,
159)
22 (10, 40) 163 (140,
183)
13 (—11, 29)
LDL, mg/dL
Mean (SD) 85 (22) 15 (26) 100 (24) 14 (27) 0.8 (—14.6, 16.3)
Median (IQR) 81 (71,
101)
17 (1, 30) 104 (79,
117)
8( —7, 33)
HDL, mg/dL
Mean (SD) 38 (13) 6 (7) 45 (14) 4 (10) 2.3 (—2.8, 7.3)
Median (IQR) 37 (28,
44)
6 (2, 10) 44 (39,
49)
2( —2, 11)
TC/HDL ratio
Mean (SD) 4.1 (1.14) 0.1 (1.06) 3.9 (1.02) —0.1 (0.75) 0.20 (—0.34, 0.75)
Median (IQR) 4.08
(3.41,
4.90)
0.05 (—0.62, 0.67) 3.87
(3.10,
4.24)
—0.08 (—0.54,
0.26)
Apo A1, mg/dL
Mean (SD) 115 (26) 12 (16) 128 (22) 3 (19) 9.7 (—0.5, 19.8)
Median (IQR) 112 (96,
127)
11 (—1, 27) 127 (112,
132)
3( —11, 19)
Apo B, mg/dL
Mean (SD) 74.5 (19) 4 (21) 81.7
(18.5)
2 (17) 2.0 (—9.3, 13.4)
Median (IQR) 72 (64,
84)
3( —3, 15) 81 (66,
95)
4( —10, 12)
Apo B/A1 ratio
Mean (SD) 0.68
(0.20)
0.68 (0.25) 0.65
(0.16)
0.66 (0.17) —0.02 (—0.125, 0.079)
Median (IQR) 0.67
(0.55,
0.82)
0.63 (0.51, 0.79) 0.64
(0.56,
0.73)
0.68 (0.54, 0.78)
Fasting glucose, fasting insulin and HOMA-
IR,
b mean (SD)
Glucose, mg/dL 89 (12) 3 (9) 90 (11) 6 (22) —3.6 (—12.8, 5.6)
Insulin, uIU/mL 6 (6) 1 (6) 9 (14) —3 (17) 3.8 (—3.0, 10.6)
HOMA-IR 1.62
(1.70)
0.04 (2.26) 2.94
(6.02)
—1.24 (8.01) 1.27 (—2.66, 5.20)
Creatinine clearance,
b mean (SD)
Creatinine clearance, mL/min 107.6
(28.7)
—0.00 (0.288) 110.9
(27.9)
—0.03 (0.244) 0.03 (—0.12, 0.18)
Biomarkers,
b mean (SD)
IL-1 Beta, pg/mL 0.2 (0.3) 0.3 (1.4) 0.3 (0.3) —0.1 (0.3) 0.40 (—0.22, 1.04)
IL-6, pg/mL 1.9 (1.9) 0.2 (7.3) 1.0 (1.3) 0.3 (0.9) —0.08 (—3.24, 3.08)
hs-CRP, mg/L 3.1 (5.2) 1.2 (11.2) 2.2 (2.5) 0.6 (5.1) 0.65 (—4.55, 5.85)
Overton et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P74
http://www.jiasociety.org/content/13/S4/P74
Page 2 of 3Table 1: (Continued)
TNF-alpha, pg/mL 4207
(1702)
—1384 (1722) 2957
(727)
—442 (722) —942.1 (—1735.3, —149.0)
LPS, pg/mL 85 (29) —18 (35) 87 (31) —17 (51) —1.4 (—25.6, 22.9)
D-dimer, ng/mL 373 (580) —192 (587) 189 (111) —24 (144) —168.0 (—432.2, 96.2)
Fibrinogen, g/L 3.3 (1.1) —0.3 (1.1) 3.2 (0.7) —0.3 (0.9) 0.02 (—0.60, 0.61)
Efficacy parameters,
b mean (SD)
Viral load, log10 copies/mL 5.0 (0.8) —3.3 (0.8) 4.6 (0.7) —2.9 (0.7) —0.4 (—0.8, 0.1)
CD4+ cell count, cells/mm
3 268.3
(144.2)
217.4 (116.8) 326.7
(174.1)
205.3 (153.5) 12.1 (—61.8, 86.1)
aLipid evaluable set;
bITT-observed (sample size varies by time point and parameter);
DRV/r, darunavir/ritonavir; ATV/r, atazanavir/ritonavir; BL, baseline; CI, confidence interval; TG, triglycerides;
SD, standard deviation; IQR, interquartile range; TC, total cholesterol; LDL, low-density lipoprotein;
HDL, high-density lipoprotein; Apo, apolipoprotein; HOMA-IR, homeostasis model assessment-estimated insulin resistance;
IL, interleukin; hs-CRP, high-sensitivity c-reactive protein; TNF, tumor necrosis factor; LPS, lipopolysaccharide;
ITT, intent-to-treat
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